Local
FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug
Meet in Common connects news with real conversations. Use ThinkMatch to arrange a Roundtable and meet people to discuss this story.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: Investor's Business Daily

The FDA said Summit Therapeutics' lung cancer drug ivonescimab, developed in China, failed to show a statistically significant survival benefit.
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at Investor's Business Daily



